What Мальтофер Фол Treats: Main Uses and Benefits

This medication is commonly used to manage conditions characterized by periods of heightened symptoms resulting from the concurrent lack of iron and folic acid in the body, which is a form of nutritional anemia. It is relevant for easing symptoms related to physical discomfort and systemic imbalance, such as chronic fatigue, extreme tiredness, and paleness. The therapeutic aim is relevant for easing symptoms related to the underlying deficiency.

---

It is commonly used to help with manifest iron deficiency anemia, latent iron deficiency (low iron stores), and for prophylactic support in contexts involving significant increase in nutrient requirements. This includes the antenatal period (pregnancy) and lactation. The use of the Iron (III) Hydroxide Polymaltose Complex (IPC) form is generally associated with improved gastrointestinal tolerability. This supports patients during difficult episodes by easing distress, which generally contributes to improved comfort during prolonged supplementation periods.

---

“The therapeutic benefit helps patients cope more steadily with the required period of supplementation.”

---

Quick Fact: Symptom Focus

This medication is applied in addressing symptoms related to physical discomfort and systemic imbalance that occur in conditions involving a combined nutritional deficit.

Who Can and Cannot Use Мальтофер Фол?

The population eligibility for Мальтофер Фол is strictly defined by regulatory authorities to prevent the risk of iron accumulation and ensure appropriate treatment.

---

Regulatory Eligibility Classifications

Classification	Population/Condition
Allowed Populations	Adults and Adolescents (12 years); Pregnant Women and Lactating Women (use is permitted).
Not Recommended	Children under 12 years (for the combined tablet/high-dose formulation).

---

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations or clinical states:

• Hypersensitivity (Allergy) to Iron (III) Hydroxide Polymaltose Complex, Folic Acid, or any excipients.
• Iron Overload conditions (e.g., Hemochromatosis, Hemosiderosis).
• Anemias Not Caused by Iron or Folic Acid Deficiency (e.g., disturbances in iron utilization, such as thalassemia or megaloblastic anemia due to B12 deficiency).
• Severe Liver and Kidney Diseases.

Mandatory Precaution: A potential Vitamin B12 deficiency must be ruled out before initiating treatment, as the folic acid component can mask the neurological symptoms of B12 deficiency, as stipulated in official labeling.

The interaction profile for this combined preparation is structured around the distinct chemical properties of both Iron (III) Hydroxide Polymaltose Complex (IPC) and Folic Acid.

Regulatory documents note that the IPC component possesses a distinctive interaction pattern, being documented as unlikely to form complexes with common food components like phytin or with substances such as tetracycline antibiotics. This reduces the ionic interaction potential often associated with traditional iron salts.

Conversely, the Folic Acid component is involved in several documented interactions. Co-administration with certain anticonvulsants, such as Phenytoin, is formally associated with a pharmacokinetic interaction that can result in a reduction of the anticonvulsant's plasma concentration. Furthermore, Folic Acid can act as an antagonist to some antineoplastic agents, including Methotrexate.

Regarding absorption, antacids containing aluminum or magnesium are documented to reduce the bioavailability of Folic Acid, necessitating a mandatory separation of administration by at least 2 hours. The regulatory labeling contains a formal restriction against the use of oral Maltofer Fol concurrently with injectable iron medicines. Folic Acid also carries a formal pharmacodynamic warning that it can mask the hematological signs of an underlying Vitamin B12 deficiency.

️ Regulated Iron Delivery and Oxygen Transport

The mechanism centers on the Iron(III)-hydroxide polymaltose complex (⑪ⓅⓂ), a stable structure that structurally mimics the body’s iron storage protein, ferritin. This structure facilitates a controlled, active-regulated uptake of Fe^3+ in the gut. The complex structure prevents the local concentration of free Fe^3+/ Fe^2+ ions, reducing localized oxidative potential. The absorbed Fe^3+ is then delivered via the carrier protein transferrin to the bone marrow, where it is incorporated into the mathbfheme group of mathbfhemoglobin, increasing the blood's capacity for systemic oxygen transport.

---

️ Folic Acid Co-factor and mathbfDNA Synthesis Support

Folic Acid acts as a necessary metabolic precursor, which is enzymatically converted to the active tetrahydrofolate (THF) co-factor by dihydrofolate reductase (DHFR). The THF co-factor is essential for one-carbon transfer reactions required for the synthesis of purine and pyrimidine nucleotides (the building blocks of DNA). This activity is necessary to ensure the appropriate cell division and maturation of red blood cell precursors, thus avoiding the morphological change characteristic of defective DNA replication.

---

Dual-Mechanism Synergy in Hematopoiesis

The overall action is a coordinated synergy where Folic Acid ensures the correct maturation and division of new red blood cell precursors by supporting DNA synthesis, while ⑪ⓅⓂ ensures the necessary elemental supply by providing the Fe^3+ required for functional mathbfHemoglobin formation. The combined action supports the sequence of steps required for mathbferythropoiesis (blood cell production).

Official Administration Guidelines

Мальтофер Фол is an oral preparation available in several official dosage forms, including tablets (chewable and non-chewable) and oral solutions (syrup or drops). The fundamental principle for administration is that the dose must be consumed during or immediately after a meal.

Dosing and Schedule

Standard adult and adolescent dosing is defined by the level of deficiency. For the treatment of manifest iron deficiency anemia, the regimen is commonly 100 mg to 200 mg of elemental iron daily. A dose of 100 mg elemental iron daily is specified for the management of latent iron deficiency or for prophylactic use, including during pregnancy. The total daily dose can be taken at once or divided into separate administrations.

For liquid forms, the solution can be mixed with fruit or vegetable juices. It is specified that 100 mg unit-dose tablets should not be divided; liquid preparations are used when lower doses are required for children or specific regimens. If a daily dose is missed, the standard procedure is to skip the missed dose and continue the regular schedule; a double dose should not be taken to compensate.

Course Duration

Therapy is structured as a prolonged course. The first phase typically continues for approximately 3 to 5 months until blood hemoglobin values are normalized. This is followed by a consolidation phase where the medication is continued for at least one month to fully replenish the body's iron stores (ferritin).

Research Evidence / Overview of Studies for Мальтофер Фол

---

Research Evidence for Manifest Iron Deficiency Anemia (IDA)

Research exploring the effects of this preparation, containing Iron (III) Hydroxide Polymaltose Complex (IPC) and Folic Acid, includes short-term Randomized Controlled Trials (RCTs) and meta-analyses. These studies were conducted primarily in adults and adolescents diagnosed with low iron stores and anemia. Researchers used these trials to examine outcomes related to systemic imbalance by monitoring key blood markers like Hemoglobin (Hb) and Serum Ferritin over defined intervals, typically 8 to 16 weeks. Studies report that changes measured in blood markers were often comparable across different oral iron formulations. Trials monitored patient-reported outcomes describing perceived discomfort, where some observed patterns of lower incidence of gastrointestinal-related symptoms in the IPC groups, and research explored the potential association between this and patient adherence.

Research Evidence in Pregnancy and Special Populations

The medicine was studied in pregnant women, a population associated with increased nutrient requirements, through comparative RCTs and evidence syntheses. These studies monitored maternal outcomes and often reported a lower rate of reported gastrointestinal-related symptoms in the IPC groups. Research has also examined the IPC component in children and adolescents. However, evidence quality varies across studies for these special groups, and research suggests that the effect of the IPC component on correcting blood markers in children under 12 years old appears to be less consistent than in adults.

Research Gaps and Unanswered Questions

The evidence base is often synthesized from data on general iron and folic acid supplementation (IFA), meaning comparative evidence is lacking to definitively separate the specific contribution of the combined Maltofer Fol formulation from IPC alone. Furthermore, most trials have limited follow-up durations, meaning long-term effects are not fully established regarding the maintenance of iron stores after treatment cessation. This includes data for deficiency prophylaxis, where evidence relies heavily on general guidelines rather than long-term trials of this specific formulation.

Key Studies & References

1. WHO Recommendation: Daily oral iron and folic acid supplementation in pregnant women (Antenatal Care)

Common questions about Мальтофер Фол (FAQ)

---

Q: When is the best time of day to take Maltofer Fol to maximize absorption?

Official product information indicates the medicine is typically administered during or immediately after a meal. Studies and official information suggest that iron absorption may be enhanced when the medication is taken with food.

---

Q: What food or drugs should I avoid while taking this medicine?

Regulatory information notes that the iron component (IPC) is unlikely to interact with many common foods. However, the Folic Acid component has documented interactions with certain types of anticonvulsant and antineoplastic agents. Regulatory documents recommend that antacids be taken at least two hours apart from this medication.

---

Q: Can I crush the tablet if I have trouble swallowing it whole?

The official product labeling indicates that the tablets should be swallowed whole and should not be halved or crushed. If a dose lower than the tablet strength is desired, or if swallowing is difficult, the liquid (oral solution or drops) preparation may be used instead.

---

Q: Are there any special considerations for taking this medicine if I have diabetes?

The product information sheet for the oral liquid (syrup) formulation contains specific warnings regarding its inactive ingredients, such as sorbitol and sucrose (sugar). The label information includes these excipient warnings as a consideration for patients with pre-existing conditions that affect sugar or carbohydrate metabolism.

---

Q: How should I safely dispose of expired Maltofer Fol?

Expired or unwanted medication should not be discarded in household trash or poured down the sink. Regulatory guidance states that expired or unwanted medication should be returned to a pharmacy or designated collection facility for safe disposal as pharmaceutical waste.

How to Store and Dispose of Мальтофер Фол (Maltofer Fol) — Regulatory Requirements

Official labeling defines strict conditions to maintain the medicine’s stability and prevent accidental ingestion.

Storage/Disposal Component	Regulatory Requirement
Temperature Condition	Must be stored in a cool, dry place where the temperature stays below 25 C (77 F).
Environmental Protection	Keep protected from heat, moisture, and direct sunlight. Do not store near a sink or on window sills.
Child Safety Mandate	Must be kept out of the sight and reach of children due to the serious risk associated with iron products.
Packaging and Stability	Store in the original container until the expiry date stated on the label; do not use past this date.
Disposal Instructions	Unused or expired product must be returned to a pharmacy for safe disposal in accordance with local requirements, and should not be discarded in household trash or wastewater.

The official storage profile mandates environmental control below 25 C and protection from humidity. The disposal process is regulated as pharmaceutical waste, requiring return to a collection facility. These constraints ensure product quality and adhere to the mandatory child-safety rule for all iron supplements.